Intervention not reported
Improvement of clinical status: participants discharged alive at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The intervention showed no clear difference in improvement of clinical status: participants discharged alive at day… (low certainty).
1 finding from 1 review
Intervention not reported
QoL at longest · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events during the trial period · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes serious adverse events during the trial period (very low certainty).
1 finding from 1 review
Intervention not reported
Any adverse events during the trial period · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The intervention showed no clear difference in any adverse events during the trial period (low certainty).
1 finding from 1 review
Intervention not reported
Viral clearance at day 7 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The intervention showed no clear difference in viral clearance at day 7 (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in all‐cause mortality at day 28 (moderate certainty).
1 finding from 1 review
Intervention not reported
Worsening of clinical status: admission to hospital or death within 28 days · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in worsening of clinical status: admission to hospital or death within… (low certainty).
1 finding from 1 review
Major procedure‐related bleeding · thrombocytopenia
1 finding from 1 review
All‐cause mortality up to 30 days after the procedure · thrombocytopenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Transfusion‐related complications within 24 hours of the procedure · thrombocytopenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Procedure‐related (lumbar puncture or epidural anaesthetic) complications within 7 days of the procedure · thrombocytopenia
1 finding from 1 review
Quality of life (as defined by the individual studies) · thrombocytopenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with 'any bleeding' event(s) (WHO grade 1 to 4 or equivalent) ‐ · thrombocytopenia
Pathogen‐reduced platelets may leads to higher number of participants with 'any bleeding' event(s) (WHO grade 1 to… compared with standard platelets (low certainty).
1 finding from 1 review
Number of participants with clinically significant bleeding · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in number of participants with 'clinically significant' bleeding… compared with standard platelets (moderate certainty).
1 finding from 1 review
Number of participants with 'severe' bleeding event(s) (WHO grade ≥ 3 or equivalent) ‐ · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in number of participants with 'severe' bleeding event(s) (WHO grade ≥… compared with standard platelets (moderate certainty).
1 finding from 1 review
All‐cause mortality · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in all‐cause mortality compared with standard platelets (moderate certainty).
1 finding from 1 review
Number of participants with a serious adverse event · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in number of participants with a serious adverse event compared with standard platelets (moderate certainty).
1 finding from 1 review
Number of participants experiencing platelet refractoriness · thrombocytopenia
Pathogen‐reduced platelets leads to higher number of participants experiencing platelet refractoriness compared with standard platelets (high certainty).
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · thrombocytopenia
1 finding from 1 review
Intervention not reported
All‐cause mortality · patients with solid tumours without thrombocytopenia before chemotherapy
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review